Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eupraxia Pharmaceuticals Inc. has secured a new C$12 million convertible debt facility aimed at strengthening its capital structure and ensuring operational funding until Q2 2025. This move comes as the company also updates on the settlement of its existing debt with Silicon Valley Bank, expecting to finalize payments by Q3 2024. The pharmaceutical company continues to progress with its clinical programs, focusing on treatments for eosinophilic esophagitis and osteoarthritis.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.